However, when expression is reduced in combination with expression of the AML-initiating fusion protein Cbfb+/56M, its loss leads to a decreased time of survival and an increased expansion of tumor cells in a secondary transplant. The gene discussed is CBFB; the disease is acute myeloid leukemia.